<li>acarbose<p>prednisone decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>alfentanil<p>prednisone will decrease the level or effect of alfentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>alfuzosin<p>prednisone will decrease the level or effect of alfuzosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>alosetron<p>prednisone will decrease the level or effect of alosetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>amitriptyline<p>prednisone will decrease the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>amlodipine<p>prednisone will decrease the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>amphotericin b deoxycholate<p>amphotericin b deoxycholate, prednisone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential for hypokalemia.</p></li><li>armodafinil<p>prednisone will decrease the level or effect of armodafinil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>aspirin<p>prednisone decreases levels of aspirin by increasing renal clearance. Minor/Significance Unknown.</p></li><li>aspirin rectal<p>prednisone decreases levels of aspirin rectal by increasing renal clearance. Minor/Significance Unknown.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>prednisone decreases levels of aspirin/citric acid/sodium bicarbonate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>atazanavir<p>prednisone will decrease the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>balsalazide<p>prednisone decreases levels of balsalazide by increasing renal clearance. Minor/Significance Unknown.</p></li><li>bendroflumethiazide<p>prednisone, bendroflumethiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>bosentan<p>prednisone will decrease the level or effect of bosentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>bumetanide<p>prednisone, bumetanide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>calcium acetate<p>prednisone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown.</p></li><li>calcium carbonate<p>prednisone decreases levels of calcium carbonate by increasing elimination. Minor/Significance Unknown.</p></li><li>calcium chloride<p>prednisone decreases levels of calcium chloride by increasing elimination. Minor/Significance Unknown.</p></li><li>calcium citrate<p>prednisone decreases levels of calcium citrate by increasing elimination. Minor/Significance Unknown.</p></li><li>calcium gluconate<p>prednisone decreases levels of calcium gluconate by increasing elimination. Minor/Significance Unknown.</p></li><li>cevimeline<p>prednisone will decrease the level or effect of cevimeline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>chlorothiazide<p>prednisone, chlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>chlorpropamide<p>prednisone decreases effects of chlorpropamide by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>chlorthalidone<p>prednisone, chlorthalidone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>choline magnesium trisalicylate<p>prednisone decreases levels of choline magnesium trisalicylate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>chromium<p>prednisone decreases levels of chromium by increasing renal clearance. Minor/Significance Unknown.</p></li><li>clarithromycin<p>prednisone will decrease the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>clomethiazole<p>prednisone will decrease the level or effect of clomethiazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>clomipramine<p>prednisone will decrease the level or effect of clomipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>colestipol<p>colestipol decreases levels of prednisone by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>cyclopenthiazide<p>prednisone, cyclopenthiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>cyclosporine<p>prednisone, cyclosporine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown.</p></li><li>danazol<p>danazol, prednisone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>dapsone<p>prednisone will decrease the level or effect of dapsone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>delavirdine<p>prednisone will decrease the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>desipramine<p>prednisone will decrease the level or effect of desipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>diflunisal<p>prednisone decreases levels of diflunisal by increasing renal clearance. Minor/Significance Unknown.</p></li><li>disopyramide<p>prednisone will decrease the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>docetaxel<p>prednisone will decrease the level or effect of docetaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>donepezil<p>prednisone will decrease the level or effect of donepezil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>dutasteride<p>prednisone will decrease the level or effect of dutasteride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>efavirenz<p>prednisone will decrease the level or effect of efavirenz by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>eplerenone<p>prednisone will decrease the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>erythromycin base<p>erythromycin base increases levels of prednisone by decreasing metabolism. Minor/Significance Unknown. Risk of toxic steroid concentrations and altered mental status.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate increases levels of prednisone by decreasing metabolism. Minor/Significance Unknown. Risk of toxic steroid concentrations and altered mental status.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate increases levels of prednisone by decreasing metabolism. Minor/Significance Unknown. Risk of toxic steroid concentrations and altered mental status.</p></li><li>erythromycin stearate<p>erythromycin stearate increases levels of prednisone by decreasing metabolism. Minor/Significance Unknown. Risk of toxic steroid concentrations and altered mental status.</p></li><li>ethacrynic acid<p>prednisone, ethacrynic acid. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>etoricoxib<p>prednisone will decrease the level or effect of etoricoxib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>eucalyptus<p>prednisone will decrease the level or effect of eucalyptus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>feverfew<p>prednisone decreases effects of feverfew by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>finasteride<p>prednisone will decrease the level or effect of finasteride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>fluoxymesterone<p>fluoxymesterone, prednisone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>furosemide<p>prednisone, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>galantamine<p>prednisone will decrease the level or effect of galantamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>glimepiride<p>prednisone decreases effects of glimepiride by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>glipizide<p>prednisone decreases effects of glipizide by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>gliquidone<p>prednisone decreases effects of gliquidone by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>glyburide<p>prednisone decreases effects of glyburide by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>hydrochlorothiazide<p>prednisone, hydrochlorothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>imipramine<p>prednisone will decrease the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>indapamide<p>prednisone, indapamide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>insulin aspart<p>prednisone decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>insulin detemir<p>prednisone decreases effects of insulin detemir by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>insulin glargine<p>prednisone decreases effects of insulin glargine by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>insulin glulisine<p>prednisone decreases effects of insulin glulisine by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>insulin lispro<p>prednisone decreases effects of insulin lispro by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>insulin nph<p>prednisone decreases effects of insulin nph by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>insulin regular human<p>prednisone decreases effects of insulin regular human by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>isoniazid<p>prednisone decreases effects of isoniazid by unknown mechanism. Minor/Significance Unknown.</p></li><li>isradipine<p>prednisone will decrease the level or effect of isradipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>itraconazole<p>prednisone will decrease the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>ketoconazole<p>prednisone will decrease the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>mesalamine<p>prednisone decreases levels of mesalamine by increasing renal clearance. Minor/Significance Unknown.</p></li><li>mesterolone<p>mesterolone, prednisone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>metformin<p>prednisone decreases effects of metformin by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>methyclothiazide<p>prednisone, methyclothiazide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>methyltestosterone<p>methyltestosterone, prednisone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>metolazone<p>prednisone, metolazone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>metyrapone<p>prednisone decreases effects of metyrapone by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>mibefradil<p>prednisone will decrease the level or effect of mibefradil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>miglitol<p>prednisone decreases effects of miglitol by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>montelukast<p>prednisone will decrease the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>nateglinide<p>prednisone decreases effects of nateglinide by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>nifedipine<p>prednisone will decrease the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>nimodipine<p>prednisone will decrease the level or effect of nimodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>nitrendipine<p>prednisone will decrease the level or effect of nitrendipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>oxandrolone<p>oxandrolone, prednisone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>oxybutynin<p>prednisone will decrease the level or effect of oxybutynin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>oxymetholone<p>oxymetholone, prednisone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>paclitaxel<p>prednisone will decrease the level or effect of paclitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>paclitaxel protein bound<p>prednisone will decrease the level or effect of paclitaxel protein bound by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>parecoxib<p>prednisone will decrease the level or effect of parecoxib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>pimozide<p>prednisone will decrease the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>pioglitazone<p>prednisone will decrease the level or effect of pioglitazone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.<span><br><br></span>prednisone decreases effects of pioglitazone by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>porfimer<p>prednisone decreases levels of porfimer by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>propafenone<p>prednisone will decrease the level or effect of propafenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>quinine<p>prednisone will decrease the level or effect of quinine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>repaglinide<p>prednisone decreases effects of repaglinide by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>rosiglitazone<p>prednisone decreases effects of rosiglitazone by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>salicylates (non-asa)<p>prednisone decreases levels of salicylates (non-asa) by increasing renal clearance. Minor/Significance Unknown.</p></li><li>salsalate<p>prednisone decreases levels of salsalate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>sargramostim<p>prednisone increases effects of sargramostim by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>saxagliptin<p>prednisone will decrease the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.<span><br><br></span>prednisone decreases effects of saxagliptin by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>sitagliptin<p>prednisone decreases effects of sitagliptin by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>somatropin<p>prednisone decreases effects of somatropin by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>sufentanil<p>prednisone will decrease the level or effect of sufentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>sulfasalazine<p>prednisone decreases levels of sulfasalazine by increasing renal clearance. Minor/Significance Unknown.</p></li><li>tacrolimus<p>prednisone, tacrolimus.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown.</p></li><li>telithromycin<p>prednisone will decrease the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>testosterone<p>testosterone, prednisone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>testosterone buccal system<p>testosterone buccal system, prednisone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>testosterone topical<p>testosterone topical, prednisone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation.</p></li><li>tolazamide<p>prednisone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>tolbutamide<p>prednisone decreases effects of tolbutamide by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>torsemide<p>prednisone, torsemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>troglitazone<p>prednisone decreases effects of troglitazone by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>troleandomycin<p>prednisone will decrease the level or effect of troleandomycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vesnarinone<p>prednisone will decrease the level or effect of vesnarinone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vildagliptin<p>prednisone decreases effects of vildagliptin by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>vinblastine<p>prednisone will decrease the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vincristine<p>prednisone will decrease the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vincristine liposomal<p>prednisone will decrease the level or effect of vincristine liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vinorelbine<p>prednisone will decrease the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>willow bark<p>prednisone decreases levels of willow bark by increasing renal clearance. Minor/Significance Unknown.</p></li><li>ziprasidone<p>prednisone will decrease the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>zonisamide<p>prednisone will decrease the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li>